Job Trends
Looking for a biopharma job in New Jersey? Check out the BioSpace list of five top companies hiring life sciences professionals like you.
Labor Market Reports
The life sciences job market continues to shift. BioSpace’s Q2 2025 U.S. Life Sciences Job Market Report is now available, offering exclusive insights into the latest hiring trends, layoffs, and workforce dynamics across the life sciences industry.
Year-over-year BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the first quarter of 2025.
The 9% average salary increase from 2023 to 2024 was the largest for life sciences professionals since 2021. Several factors could be behind the spike, including companies providing higher pay because bonuses and stock compensation went down.
Now Hiring
Looking for a biopharma job in North Carolina? Check out the BioSpace list of seven companies hiring life sciences professionals like you.
Looking for a biopharma job in California? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
Looking for a biopharma job in Illinois? Check out the BioSpace list of six companies hiring life sciences professionals like you.
Career Advice
Remember, though it may be a tad uncomfortable in the moment, being gracious and polite while you decline a job offer can build good karma for the future.
THE LATEST
Life science jobs are booming in several regions around the U.S. One is the Pacific Northwest, specifically Oregon; another is the Philadelphia area. Here’s a look.
Significant contributions were made to the Series A by Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management.
Sanofi’s troubles stemming from the 2019 recall of Zantac appear to be far from over.
BioNTech will open a state-of-the-art manufacturing facility in Singapore to support a global supply of mRNA-based vaccines and therapeutics.
Since emerging from stealth mode in 2020 Dyno Therapeutics has been busy advancing its gene therapy platform. This morning, the company bolsters its research with $100 million raised in a Series A financing round.
The U.S. FDA approved Keytruda combined with Genentech’s Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy, for first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Fueled by billions of dollars invested by the federal government to battle the ongoing COVID-19 pandemic, companies across the BioCapital region have expanded their footprint and number of employees.
Should this antibody continue to prove to be safe and effective in clinical studies, it will replace the previously authorized bamlanivimab, which has since been sidelined due to the rise of viral variants that diminished its effectiveness.
The regulatory nod marks the first time the FDA approved an SGLT2 inhibitor for the treatment of CKD regardless of diabetes status.
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.